May 2014
Nephrology Dialysis Transplantation;May2014, Vol. 29 Issue suppl_3, piii491
Academic Journal
No abstract available.


Related Articles

  • Once-monthly continuous erythropoietin receptor activator (CERA) for haemoglobin maintenance in haemodialysis patients with chronic renal anaemia. Duman, Neval; Uyanik, Abdullah; Unsal, Abdulkadir; Sezer, Siren; Camsari, Taner; Cirit, Mustafa; Yilmaz, Mehmet Emin; Altun, Bülent; Duranay, Murat; Yildiz, Alaattin; Sahin, Idris; Dogukan, Ayhan; Ustundag, Sedat; Karayaylali, Ibrahim; Kahveci, Arzu; Sindel, Sukru; Kiykim, Ahmet Alper; Yenicerioglu, Yavuz; Akbas, Ertugrul; Ozdener, Fatih // Clinical Kidney Journal;Oct2014, Vol. 7 Issue 5, p464 

    Background This study was conducted to evaluate the efficacy and safety of once-monthly continuous erythropoietin receptor activator (CERA) for maintenance of stable haemoglobin (Hb) levels in adult chronic renal anaemia patients on dialysis according to local clinical judgment in Turkey....

  • Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial. Forni, Valentina; Bianchi, Giorgia; Ogna, Adam; Salvadé, Igor; Vuistiner, Philippe; Burnier, Michel; Gabutti, Luca // BMC Nephrology;2013, Vol. 14 Issue 1, p1 

    Background: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however...

  • Erythropoietin use and abuse. John, M. Joseph; Jaison, Vineeth; Jain, Kunal; Kakkar, Naveen; Jacob, Jubbin J. // Indian Journal of Endocrinology & Metabolism;Mar2012, Vol. 16 Issue 2, p220 

    Recombinant human erythropoietin (rhEPO) is arguably the most successful therapeutic application of recombinant DNA technology till date. It was isolated in 1977 and the gene decoded in 1985. Since then, it has found varied applications, especially in stimulating erythropoiesis in anemia due to...

  • Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Carrera, Fernando; Disney, Alex; Molina, Manuel // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_4, piv19 

    The recombinant human erythropoietins epoetins alfa and beta have relatively short half-lives (∼24 h by subcutaneous route) and have traditionally been administered 2 or 3 times a week for the treatment of anaemia in patients with chronic kidney disease. However, multiple weekly injections...

  • A combined model of human erythropoiesis and granulopoiesis under growth factor and chemotherapy treatment. Schirm, Sibylle; Engel, Christoph; Loeffler, Markus; Scholz, Markus Scholz // Theoretical Biology & Medical Modelling;2014, Vol. 11 Issue 1, p2 

    Background Haematotoxicity of conventional chemotherapies often results in delays of treatment or reduction of chemotherapy dose. To ameliorate these side-effects, patients are routinely treated with blood transfusions or haematopoietic growth factors such as erythropoietin (EPO) or granulocyte...

  • Foreword. Carrera, Fernando // Nephrology Dialysis Transplantation;2007, Vol. 22 Issue suppl_4, piv1 

    An introduction to the journal is presented in which the editor discusses an article on haemoglobin (Hb) level stability because of erythropoiesis-stimulating agents (ESA), half-life of darbepoetin, and extended dosage of ESAs.

  • An observational cohort study of extended dosing (once every 2 weeks or once monthly) regimens with darbepoetin alfa in patients with chronic kidney disease not on dialysis: the EXTEND study. Galle, Jan-Christoph; Claes, Kathleen; Kiss, Istvan; Winearls, Christopher G.; Herlitz, Hans; Guerin, Alain; Di Giulio, Salvatore; Suranyi, Michael G.; Bridges, Ian; Addison, Janet; Farouk, Mourad // Nephrology Dialysis Transplantation;Jun2012, Vol. 27 Issue 6, p2303 

    Background. Darbepoetin alfa (DA) has been shown to be an effective treatment of anaemia in patients with chronic kidney disease (CKD) not on dialysis (NoD). EXTEND is an observational study assessing the effectiveness of DA administered once biweekly (Q2W) or monthly (QM) in a general CKD-NoD...

  • Managing chemotherapy induced anemia with darbepoetin alfa and other erythropoiesis stimulating agents: a nurse's perspective. Derbyshire, Loraine; Thain, Colin W. // Nursing: Research & Reviews;2013, Vol. 3, p155 

    Chemotherapy induced anemia (CIA) is a frequent complication of anticancertreatment, but often remains untreated. The main presenting symptom of CIA is fatigue, andthis can have profound implications upon chemotherapy treatment compliance and patients'quality of life (QoL). Nevertheless, a...

  • Effects of three kinds of erythropoiesis-stimulating agents on renal anemia in Japanese non-dialysis chronic kidney disease patients. Kuwahara, Michio; Hasumi, Syoko; Mandai, Shintaro; Tanaka, Tomomi; Shikuma, Satomi; Akita, Wataru; Mori, Yoshihiro; Sasaki, Sei // Clinical & Experimental Nephrology;Oct2014, Vol. 18 Issue 5, p755 

    Background: Erythropoiesis-stimulating agents (ESAs) are standard therapy for chronic kidney disease (CKD) patients with renal anemia. However, few studies have compared the effects of different ESAs on anemia in identical pre-dialysis CKD patients. Methods: Seventy-nine patients who switched...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics